Haemonetics Just Got a $96 BTIG Target-Is This Blood-Management Compounder Still Buyable Near Highs?

BTIG's $96 target comes after real execution, not just optimism

BTIG lifted Haemonetics to $96 from $84 while keeping a Buy rating. The move followed adjusted earnings per share of $1.14 exceeded consensus by six cents and 5.5% year over year revenue growth. With shares around $84.66, near their 12-month high of $88.58, this looks more like a conviction upgrade than a cheap-stock trade.

That also explains the setup's limits. BTIG's new target implies only 13.39% potential upside from the reported share price. Investors are not being asked to buy discarded value here; they are deciding whether Haemonetics can still grow into a premium valuation.

Why the quarter mattered enough to move estimates

Revenue breadth forced the model update

The key change was not just the headline EPS beat. BTIG highlighted first-quarter revenue of $339.4 million versus $327.9 million consensus. Just as important, All segments surpassed estimates, which matters more than a single strong quarter when the stock is already near its highs.

The segment mix matters to both sides of the trade

• Apheresis: Apheresis sales reached $191.3 million, with Plasma contributing $155.5 million
• MedSurg: Interventional Technologies generating $59.9 million and Blood Management Technologies posting $88.1 million
• Turnaround signal: Interventional Technologies returned to growth, rising 2.5% year-over-year on a reported basis and 2.8% organically
• Plasma quality: Plasma revenue benefited from market share gains, increased volume, and pricing

That mix is why the upgrade is easy to understand. Growth was broad-based, and the part of the business bears had singled out was no longer flattish.

The higher target rests on a better forward path

Haemonetics also raised its fiscal 2027 guidance, increasing reported revenue growth expectations to 5% to 8% from a prior range of 4% to 7%. It kept its outlook for 50 to 100 basis points of adjusted EBIT margin expansion and approximately 80% free cash flow conversion. That is the simple bridge from a good quarter to a higher target: more revenue, still-improving margins, and strong cash conversion.

Of course, the risks are still visible. Recent commercial stumbles have led to scrutiny in the Interventional Technologies sub-segment, and Haemonetics is facing strong competition in the blood center segment. Those concerns do not erase the quarter, but they do mean the stock no longer deserves credit for a turnaround without continued proof.

The debate now is valuation versus earning power

Why bulls still have a case

The bull case is not that Haemonetics is cheap. It is that the earnings trajectory may still justify a premium. BTIG's target is now $96, up from $88.00 earlier this year, and Mizuho boosted their price objective on shares of Haemonetics from $85.00 to $90.00. That does not make the stock inexpensive, but it does suggest recent estimates are moving the right way.

Why bears still have ammunition

The clearest bear argument is valuation. Haemonetics trades at roughly 41.54 times earnings. At that level, the market has little room to forgive execution misses or slowing breadth.

Bears can also lean on strong competition in the blood center segment and the same recent commercial stumbles that still make Interventional Technologies harder to underwrite. That is not thesis-killing on its own, but it does argue for discipline.

What to watch before chasing the move

This reads more like a watchlist name than a blind chase. The case improves if Haemonetics adds another quarter of broad-based execution. It weakens if growth narrows, margins stall, or the weaker businesses slip again.

What could still support a move toward $96: - another quarter of broad-based execution - rising analyst targets, now ranging from $62 to $104 - continued proof that the premium multiple is being earned

What would weaken the setup: - a miss after the stock trades at 41.54 times earnings - loss of breadth across the business - renewed weakness in the segments bears have flagged, especially Interventional Technologies and the blood center segment